Bris­tol My­ers push­es back ‘peak’ for new prod­uct sales, cit­ing chal­leng­ing up­take for So­tyk­tu, Camzyos

Bris­tol My­ers Squibb is fac­ing sev­er­al ques­tions about its mid-term fu­ture af­ter it de­layed sales pro­jec­tions for its new prod­uct port­fo­lio, which in­cludes Re­blozyl and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER